Your browser doesn't support javascript.
loading
Mitoxantrone-Loaded Nanoferritin Slows Tumor Growth and Improves the Overall Survival Rate in a Subcutaneous Pancreatic Cancer Mouse Model.
Conti, Giamaica; Pitea, Martina; Ossanna, Riccardo; Opri, Roberta; Tisci, Giada; Falvo, Elisabetta; Innamorati, Giulio; Ghanem, Esther; Sbarbati, Andrea; Ceci, Pierpaolo; Fracasso, Giulio.
Affiliation
  • Conti G; Department of Neurological and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Pitea M; Department of Biochemical Sciences, University Sapienza, 00185 Rome, Italy.
  • Ossanna R; Center for Life Nano Science@Sapienza Istituto Italiano di Tecnologia, 00161 Rome, Italy.
  • Opri R; Department of Neurological and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Tisci G; Department of Medicine, University of Verona, 37134 Verona, Italy.
  • Falvo E; Department of Biochemical Sciences, University Sapienza, 00185 Rome, Italy.
  • Innamorati G; Institute of Molecular Biology and Pathology, CNR-National Research Council of Italy, 00185 Rome, Italy.
  • Ghanem E; Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Section of Surgery, University of Verona, 37134 Verona, Italy.
  • Sbarbati A; Department of Sciences, Notre Dame University-Louaize, Zouk Mosbeh P.O. Box 72, Lebanon.
  • Ceci P; Department of Neurological and Movement Sciences, University of Verona, 37134 Verona, Italy.
  • Fracasso G; Institute of Molecular Biology and Pathology, CNR-National Research Council of Italy, 00185 Rome, Italy.
Biomedicines ; 9(11)2021 Nov 05.
Article in En | MEDLINE | ID: mdl-34829851
Pancreatic cancer (PC) represents an intriguing topic for researchers. To date, the prognosis of metastasized PC is poor with just 7% of patients exceeding a five-year survival period. Thus, molecular modifications of existing drugs should be developed to change the course of the disease. Our previously generated nanocages of Mitoxantrone (MIT) encapsulated in human H-chain Ferritin (HFt), designated as HFt-MP-PASE-MIT, has shown excellent tumor distribution and extended serum half-life meriting further investigation for PC treatment. Thus, in this study, we used the same nano-formulation to test its cytotoxicity using both in vitro and in vivo assays. Interestingly, both encapsulated and free-MIT drugs demonstrated similar killing capabilities on PaCa44 cell line. Conversely, in vivo assessment in a subcutaneous PaCa44 tumor model of PC demonstrated a remarkable capability for encapsulated MIT to control tumor growth and improve mouse survival with a median survival rate of 65 vs. 33 days for loaded and free-MIT, respectively. Interestingly, throughout the course of mice treatment, MIT encapsulation did not present any adverse side effects as confirmed by histological analysis of various murine tissue organs and body mass weights. Our results are promising and pave the way to effective PC targeted chemotherapy using our HFt nanodelivery platforms.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomedicines Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomedicines Year: 2021 Document type: Article